Arca
Skip to content
Tools
Tools

NR1H4: Bile acid receptor

Ligand-activated transcription factor.

  • Drugs that act on it: 9
  • Approved: 3
  • In phases 1 to 3: 6
  • Sponsors: 7

Who is on it, and how far along

Every drug ChEMBL records acting on NR1H4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 9

Approved3

  • Ursodiol
  • Obeticholic acid
  • Chenodiol

Phase 31

  • Cilofexor

Phase 25

  • Nidufexor
  • PX-102
  • TERN-101
  • Tropifexor
  • Turofexorate isopropyl

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Phenex Pharmaceuticals AG111%
    • Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)111%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Bile acid receptor FXR agonist.
    UrsodiolApprovedTeva Pharmaceutical IndustriesSmall moleculeAgonist42
    Obeticholic acidWithdrawn Boxed warningApprovedAlfasigmaSmall moleculeAgonist3
    ChenodiolBoxed warningApprovedLeadiant BiosciencesSmall moleculeAgonist1
    CilofexorPhase 3Gilead SciencesSmall moleculeAgonist1
    NidufexorPhase 2Novartis PharmaceuticalsSmall moleculeAgonist0
    PX-102Phase 2Phenex Pharmaceuticals AGSmall moleculeAgonist0
    TERN-101Phase 2Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Small moleculeAgonist0
    TropifexorPhase 2Novartis PharmaceuticalsSmall moleculeAgonist0
    Turofexorate isopropylPhase 2—Small moleculeAgonist0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
    Clinical Profile of Patients With MASLD in Kazakhstan and Clinical Effectiveness of Ursosan in AlmatyUrsodiol—RecruitingKazakh Association of Internal Medicine SpecialistsOct 22, 2026
    Effect of Adjunctive Ursodeoxycholic Acid on Oxidative Stress, Inflammation, and Organ Dysfunction in Adults With SepsisUrsodiolPhase 2 / Phase 3Not yet recruitingTanta UniversityOct 1, 2026
    Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisCilofexorPhase 2RecruitingGilead SciencesSep 25, 2026
    Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary CholangitisUrsodiolPhase 1 / Phase 2Not yet recruitingBeijing 302 HospitalAug 31, 2026
    Ursodeoxycholic Acid in Barrett's EndotherapyUrsodiol—Not yet recruitingColumbia UniversityAug 11, 2026
    Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerUrsodiolPhase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityJul 21, 2026
    Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal TumorsUrsodiolPhase 2RecruitingJinling Hospital, ChinaJun 29, 2026
    Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration in Adult Living Donor Liver Transplant (LDLT) Recipients.UrsodiolNot applicableNot yet recruitingInstitute of Liver and Biliary Sciences, IndiaJun 23, 2026
    Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral HepatitisUrsodiolNot applicableNot yet recruitingCombined Military Hospital, PakistanApr 13, 2026
    A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).ChenodiolPhase 4RecruitingMyungmoon Pharma. Co. Ltd.Jun 5, 2025
    Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler OutcomesObeticholic acidPhase 3Not yet recruitingAssiut UniversityNov 15, 2024
    Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic SteatohepatitisObeticholic acidPhase 2Active, not recruitingTanta UniversityOct 10, 2022
    Obeticholic Acid for Prevention in Barrett's EsophagusObeticholic acidPhase 2RecruitingNational Cancer Institute (NCI)Jun 25, 2021

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Progressive familial intrahepatic cholestasis type 10.48
    • Ciliopathy0.46
    • Cerebrotendinous xanthomatosis0.46
    • Chronic hepatitis C virus infection0.43
    • Cholelithiasis0.38
    • Cholangitis0.37
    • Inborn errors of metabolism0.37
    • Type 2 diabetes mellitus0.36

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2047, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. Gene name, function (UniProt Q96RI1, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.